These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6839551)

  • 21. Differential effect of type I and type II diabetes mellitus on antipyrine elimination.
    Adithan C; Danda D; Shashindran CH; Bapna JS; Swaminathan RP; Chandrasekar S
    Methods Find Exp Clin Pharmacol; 1989 Dec; 11(12):755-8. PubMed ID: 2626081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.
    Vesell ES; Passananti GT; Glenwright PA; Dvorchik BH
    Clin Pharmacol Ther; 1975 Sep; 18(3):259-72. PubMed ID: 1164816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anomalous results of studies on drug interaction in man. III. Disulfiram and antipyrine.
    Vesell ES; Passananti T; Glenwright PA
    Pharmacology; 1975; 13(6):481-91. PubMed ID: 1221431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucose tolerance and insulin response to glucose load before and after enzyme inducing therapy in subjects with glucose intolerance and patients with NIDDM having hyperinsulinemia or relative insulin deficiency.
    Sotaniemi EA; Karvonen I
    Diabetes Res; 1989 Jul; 11(3):131-9. PubMed ID: 2697484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipyrin clearance in homozygous beta-thalassemia.
    Rifkind AB; Canale V; New MI
    Clin Pharmacol Ther; 1976 Oct; 20(4):476-83. PubMed ID: 975719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antipyrine elimination in saliva after low-dose combined or progestogen-only oral contraceptive steroids.
    Chambers DM; Jefferson GC; Chambers M; Loudon NB
    Br J Clin Pharmacol; 1982 Feb; 13(2):229-32. PubMed ID: 7059420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipyrine clearance and metabolism in patients with psoriasis.
    Kubota K; Ishizaki T; Chiba K; Takagi A; Nakagawa A; Nakamura K
    Br J Clin Pharmacol; 1986 Oct; 22(4):455-62. PubMed ID: 3768257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipyrine kinetics in undernourished diabetics.
    Shobha JC; Raghuram TC; Kumar AD; Krishnaswamy K
    Eur J Clin Pharmacol; 1991; 41(4):359-61. PubMed ID: 1804653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.
    Posner J; Danhof M; Teunissen MW; Breimer DD; Whiteman PD
    Br J Clin Pharmacol; 1987 Jul; 24(1):51-5. PubMed ID: 3620285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism.
    Rivière JH; Back DJ; Breckenridge AM; Howells RE
    Br J Clin Pharmacol; 1985 Nov; 20(5):469-74. PubMed ID: 3878153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microsomal enzymes in patients with acute leukemia as determined by plasma half-life of antipyrine.
    Higuchi T; Nakamura T; Uchino H
    Cancer Chemother Pharmacol; 1980; 5(1):55-9. PubMed ID: 6936094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of age and sex on metabolism and urinary excretion of antipyrine.
    Jorquera F; Almar M; Pozuelo M; Sansegundo D; González-Sastre M; González-Gallego J
    J Gerontol A Biol Sci Med Sci; 1998 Jan; 53(1):M14-9. PubMed ID: 9467428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pilot study of the effect of antipyrine on caffeine kinetics in six healthy volunteer subjects.
    Soto J; Alsar MJ
    J Clin Pharm Ther; 1997 Jun; 22(3):191-5. PubMed ID: 9447474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction.
    Hepner GW; Vesell ES
    Am J Dig Dis; 1975 Jan; 20(1):9-12. PubMed ID: 1115054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Influence of ranitidine on antipyrine metabolism (author's transl)].
    Staiger C; Simon B; de Vries J; Kather H; Walter E
    Z Gastroenterol; 1980 Dec; 18(12):601-4. PubMed ID: 6116365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man.
    van Boxtel CJ; Wilson JT; Lindgren S; Sjöqvist F
    Eur J Clin Pharmacol; 1976 Feb; 9(4):327-32. PubMed ID: 971716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin sensitivity and insulin clearance in cystic fibrosis patients with normal and diabetic glucose tolerance.
    Lanng S; Thorsteinsson B; Røder ME; Nerup J; Koch C
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):217-23. PubMed ID: 7923827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antipyrine disposition in milk and saliva of lactating women.
    Berlin CM; Vesell ES
    Clin Pharmacol Ther; 1982 Jan; 31(1):38-44. PubMed ID: 7053302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of phenobarbital steady state levels on antipyrine clearance and distribution in the rat.
    Pei YY; Bialer M; Levy RH
    Biopharm Drug Dispos; 1986; 7(1):11-9. PubMed ID: 3955196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of antipyrine in epileptic patients.
    Rimmer EM; Routledge PA; Tsanaclis LM; Richens A
    Br J Clin Pharmacol; 1986 May; 21(5):511-4. PubMed ID: 3718808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.